Skip to main content
. 2022 Jun 29;12(7):914. doi: 10.3390/biom12070914

Figure 3.

Figure 3

Deaf mice recover broad spectrum auditory capacity with AAV2/9-PHP.B-CB6-hTMC1 gene therapy. ABR (A–D) or DPOAE (E–H) thresholds as a function of frequency of Tmc1Δ/Δ (A,B) (E,F) and Tmc1N193I/N193I (C,D), (G,H) mice injected at P1-2 with CB6-hTMC1 + WPRE (A,C,E,G) or CB6-hTMC1 (No WPRE) (B,D,F,H) at 4 weeks of age. Mean ± S.E.M. thresholds shown in bold traces and individual recording are shown as lighter traces. Mean ± S.E.M. ABR (I–L) or DPOAE (M–P) thresholds versus frequency for injected 4-, 8-, and 12-week-old mice. Dashed lines indicate mean ABR or DPOAE thresholds for uninjected control mice: Tmc1Δ/Δ (orange), Tmc1+/+ (black) (4-week-old: (A,B,E,F); 8-week-old: (I,M); 12-week-old: (J,N)) and Tmc1N193I/N193I (red), Tmc1N193I/+ (blue) (4-week-old: (C,D,G,H); 8-week-old: (K,O); 12-week-old: (L,P)).